Locations
Birkerød, Denmark · Capital Region of Denmark, Denmark
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series A
founded in
2008
Reapplix is a research and development company focused on personalized wound healing, particularly for diabetic foot ulcers. Their key product, the 3C Patch®, utilizes a small sample of the patient's blood to create a solid patch that accelerates wound healing. This evidence-based treatment is clinically proven and recommended by the International Working Group on the Diabetic Foot, positioning Reapplix as a leader in the wound care market. The company differentiates itself through its innovative use of autologous blood components, offering a cost-effective solution that enhances the body's natural healing process.
Something looks off?